| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-08-08 | Radius Health (USA - MA) | $300 million | private placement | Bone diseases - Cancer - Oncology - Endocronological diseases | Private placement | |
| 2017-08-07 | Cuorips (Japan) | investment | Daiichi Sankyo (Japan) | Fundraising | ||
| 2017-08-04 | Lonza (Switzerland) | € 700 million and $ 200 million | private placement | Technology - Services | Company acquisition | |
| 2017-08-01 | Homology Medicines (USA - MA) | $83.5 million | series B financing round | 5AM Ventures (USA - CA) Alexandria Venture Investments (USA - MA) ARCH Venture Partners (USA - IL) Deerfield Management (USA - NY) Fidelity Management and Research Company (US - MA) HBM Healthcare Investments (Switzerland) Maverick Ventures USA - CA) Novartis (Switzerland) Rock Springs Capital (USA - MD) Vida Ventures (Canada) Vivo Capital (USA - CA) | Rare diseases - Genetic diseases | Series B financing round |
| 2017-07-31 | Neovacs (France) | €6.0 million | private placement | undisclosed U.S. institutional investors | Autoimmune diseases | Private placement |
| 2017-07-28 | Iteos Therapeutics (Belgium) | € 7.5 million | grant | Walloon Region (Belgium) | Cancer - Oncology | Grant |
| 2017-07-26 | Quantum Genomics (France) | € 8.2 Million | capital increase | Cardiovascular diseases | Capital increase | |
| 2017-07-25 | Antabio (France) | up to $8.9 million | grant | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) | Infectious diseases | Grant |
| 2017-07-25 | Debiopharm (Switzerland) | up to $ 4 million | grant | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) | Infectious diseases | Grant |
| 2017-07-25 | Achaogen (USA - CA) | up to $ 11.5 million | grant | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) | Infectious diseases | Grant |
| 2017-07-25 | Bugworks Research Inidia (India) | up to $ 6.2 million | grant | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) | Infectious diseases | Grant |
| 2017-07-25 | Eligochem (UK) | up to $ 4.8 million | grant | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) | Infectious diseases | Grant |
| 2017-07-25 | Iterum Therapeutics (Ireland) | up to $ 1.5 million | grant | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) | Infectious diseases | Grant |
| 2017-07-25 | VenatoRx Pharmaceuticals (USA - PA) | up to $ 9.4 million | grant | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB - X) (USA - MA) | Infectious diseases | Grant |
| 2017-07-19 | Ose Immunotherapeutics (France) | €9.2 million | grant | Bpifrance (France) | Cancer - Oncology | Grant |
| 2017-07-19 | Akcea Therapeutics (USA - MA) | $193.8 million | IPO - private placement | Cardiovascular diseases - Metabolic diseases - Rare diseases | IPO | |
| 2017-07-18 | Eurofins Scientific (Luxembourg) | € 65 million | fundraising | Technology - Services | Fundraising | |
| 2017-07-18 | Neurovive Pharmaceutical (Sweden) | SEK 9 million (€ 0.94 million) | private placement | Esousa Holdings (USA - NY) | Rare diseases - Genetic diseases - Liver diseases - Hepatic diseases | Private placement |
| 2017-07-17 | Paion (Germany) | € 8 million | private placement | two undisclosed U.S. institutional investors | CNS diseases | Private placement |
| 2017-07-07 | Biophytis (France) | € 18,7 million | capital increase - private placement | Bracknor Investment Group (Dubai) | Ageing diseases - Muscle disorders - Ophtalmological diseases | Capital increase |
